China Pharma Holdings forecast that its Q3 revenues would grow between 40% and 45% over the year-previous figures. That would be a better performance than Q2, during which revenues climbed 32%. In the first quarter, however, China Pharma reported a 60% jump in its top line. The single analyst who follows China Pharma is predicting a 33% gain in Q3. An increase to 40% growth would take the company’s revenues $500,000 higher to approximately $11.5 million. More details...

Stock Symbol: (OTCBB: CPHI)